Biotech Financial Statements From 2010 to 2025

Stocks . UK . 
Stock . The Biotech Growth
BIOG Stock   867.00  7.00  0.81%   
Biotech Growth financial statements provide useful quarterly and yearly information to potential The Biotech Growth investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biotech Growth financial statements helps investors assess Biotech Growth's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biotech Growth's valuation are summarized below:
Gross Profit
-32.4 M
Profit Margin
0.9285
Exchange Market
LSE - MAIN MARKET
Market Capitalization
257.8 M
Enterprise Value Revenue
2.97
There are over sixty-seven available fundamental signals for The Biotech Growth, which can be analyzed over time and compared to other ratios. All traders should validate Biotech Growth's prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.

Biotech Growth Total Revenue

97.02 Million

Check Biotech Growth financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biotech Growth's main balance sheet or income statement drivers, such as Interest Expense of 1.3 M, Selling General Administrative of 2 M or Total Revenue of 97 M, as well as many indicators such as . Biotech financial statements analysis is a perfect complement when working with Biotech Growth Valuation or Volatility modules.
  
This module can also supplement various Biotech Growth Technical models . Check out the analysis of Biotech Growth Correlation against competitors.

Biotech Growth Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets314.4 M473.1 M389.5 M
Slightly volatile
Total Current Liabilities63.4 M60.4 M26 M
Slightly volatile
Total Stockholder Equity289.5 M415.5 M357.1 M
Slightly volatile
Cash And Short Term Investments2.6 M2.5 M2.5 M
Slightly volatile
Net Receivables17.5 M16.7 M6 M
Slightly volatile
Common Stock Total Equity14.8 M12 M13 M
Slightly volatile
Common Stock Shares Outstanding41.2 M32.4 M49.8 M
Slightly volatile
Liabilities And Stockholders Equity314.4 M473.1 M389.5 M
Slightly volatile
Other Stockholder Equity104.2 M119 M112.6 M
Pretty Stable
Total Liabilities60.5 M57.6 M34.2 M
Slightly volatile
Total Current Assets20.1 M19.2 M6.9 M
Slightly volatile
Common Stock10.3 M7.5 M12.3 M
Slightly volatile
Short and Long Term Debt Total56.8 M54.1 M30.3 M
Slightly volatile
Non Current Assets Total338.7 M454 M385.4 M
Slightly volatile
Non Current Liabilities Total56.8 M54.1 M30.3 M
Slightly volatile
Other Current Assets23.1 K24.3 K82 K
Slightly volatile
Other Assets29.5 K31.1 K53.7 M
Pretty Stable
Accumulated Other Comprehensive Income330.2 M288 M279.4 M
Slightly volatile
Short Term Debt31.7 M54.1 M30.4 M
Pretty Stable
Net Tangible Assets344.6 M297.3 M436.4 M
Slightly volatile
Long Term Investments365.1 M355.3 M476 M
Slightly volatile
Net Invested Capital350.9 M367.5 M429.1 M
Slightly volatile
Capital Stock8.2 M7.5 M11.3 M
Slightly volatile

Biotech Growth Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense1.3 M1.3 M480.8 K
Slightly volatile
Selling General Administrative2 M3.6 M2.2 M
Slightly volatile
Other Operating Expenses3.8 M4.4 M4.5 M
Slightly volatile
Income Tax Expense135.3 K182.8 K142.7 K
Slightly volatile
Tax Provision139.6 K143.1 K210.3 K
Slightly volatile
Selling And Marketing Expenses72 K81.7 K62.7 K
Slightly volatile

Biotech Fundamental Market Drivers

Cash And Short Term Investments2.1 M

About Biotech Growth Financial Statements

Biotech Growth shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Biotech Growth investors may analyze each financial statement separately, they are all interrelated. The changes in Biotech Growth's assets and liabilities, for example, are also reflected in the revenues and expenses on on Biotech Growth's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-42.2 M-44.3 M
Total Revenue92.4 M97 M
Cost Of Revenue3.6 M3.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
FFord Motor
GMGeneral Motors
SSentinelOne

Additional Tools for Biotech Stock Analysis

When running Biotech Growth's price analysis, check to measure Biotech Growth's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Growth is operating at the current time. Most of Biotech Growth's value examination focuses on studying past and present price action to predict the probability of Biotech Growth's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Growth's price. Additionally, you may evaluate how the addition of Biotech Growth to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY